Globus Med Inc Stock Price, News & Analysis

Globus Medical (NYSE: GMED) will announce its Q1 2023 financial results on May 4, 2023, after market close. A teleconference is scheduled for the same day at 4:30 p.m. ET, allowing investors to discuss the results. The conference call will be streamed live via the company's website. Participants can also join via telephone by registering for the event. Globus Medical specializes in musculoskeletal solutions and was founded in 2003. The company emphasizes its dedication to product innovation for surgeon-assisted healing. A recording of the call will be available on the investor page following the event. For further information, details are accessible on the company’s website.

Globus Medical (NYSE: GMED) announced its financial results for Q4 and full year 2022, reporting worldwide net sales of $274.5 million for Q4, a 9.8% increase year-over-year, and $1,022.8 million for the full year, a 6.8% rise. GAAP net income for Q4 soared to $50.1 million, a 231.4% increase from the prior year, while diluted EPS was $0.49. The company achieved non-GAAP diluted EPS of $0.59. Free cash flow for 2022 reached $104.4 million, with no debt reported. Looking ahead, Globus forecasts 2023 net sales of $1.1 billion and non-GAAP diluted EPS of $2.30.

The merger between Globus Medical (GMED) and NuVasive (NUVA) will form a leading musculoskeletal technology company, enhancing innovation in patient care. Under the all-stock agreement, NuVasive shareholders will receive 0.75 shares of Globus Medical for each share held, implying a price of $57.72 and an equity value of $3.1 billion. The new entity aims to capitalize on a $50 billion market, with combined net sales growth projected at 6-8% for 2023. This transaction is expected to close mid-2023, pending regulatory and shareholder approval.

Globus Medical (NYSE:GMED) will announce its financial results for Q4 and full year ended December 31, 2022, after market close on February 21, 2023. Investors can access the release on the company's website. A teleconference will be held at 4:30 p.m. ET to discuss the results, with live access available through the Investors page. Participants can join via telephone after pre-registration. Globus Medical is recognized for its musculoskeletal solutions, focused on enhancing surgical outcomes. Further information about their products and initiatives can be found on their website.

Globus Medical, a leader in musculoskeletal solutions, reported Q3 2022 financial results with worldwide net sales of $254.1 million, marking a 10.6% increase year-over-year. U.S. net sales rose by 9.5%, and international sales surged by 17.7%. GAAP net income was $47.4 million, a 0.5% increase, with diluted EPS at $0.47. The company reaffirmed its full-year guidance of $1.025 billion in sales but lowered non-GAAP diluted EPS guidance to $2.03 due to unfavorable currency impacts. The company remains debt-free.